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Abstract
Background. The homozygous deletion of Pkd1 in the
mouse results in embryonic lethality with renal cysts
and hydrops fetalis, but there is no precise data on the
segmental origin of cysts and potential changes associat-
ed with polyhydramnios.
Methods.We used Pkd1-null mice to investigate cystogen-
esis and analyze the amniotic fluid composition from em-
bryonic day 12.5 (E12.5) to birth (n = 257 embryos).
Results. Polyhydramnios was consistently observed from
E13.5 in Pkd1−/− embryos, in absence of placental abnor-
malities but with a significantly higher excretion of sodi-
um and glucose from E13.5 through E16.5, and increased
cyclic adenosine 3'5-monophosphate (cAMP) levels at
E14.5 and E15.5. The Pkd1−/− embryos started to die at
E13.5, with lethality peaking at E15.5, corresponding to
the onset of cystogenesis. The first cysts in Pkd1−/−
kidneys emerged at E15.5 in mesenchyme-derived seg-
ments at the cortico-medullary junction, with a majority
of glomerular cysts and fewer proximal tubule cysts (pos-
itive for megalin). The cysts extended to ureteric bud-de-
rived collecting ducts (positive for Dolichos biflorus
agglutinin lectin) from E16.5.
Conclusions. These studies indicate that Pkd1 deletion is
associated with a massive loss of solutes (from E13.5) and
increased cAMP levels (E14.5) associated with polyhy-
dramnios. These abnormalities precede renal cysts
(E15.5), first derived from glomeruli and proximal tubules
and later from the collecting ducts, reflecting the expres-
sion pattern of Pkd1 in maturing epithelial cells.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
is one of the most prevalent monogenic disorders, leading
to end-stage renal disease in approximately half of the
affected patients [1]. ADPKD is caused by mutations of
either PKD1 or PKD2, the genes that encode polycystin-1
and polycystin-2, respectively. These two proteins, which
are located in the primary cilium, interact in vivo to regu-
late the proliferation and differentiation of renal tubular
cells via various signalling pathways [2]. PKD1 and
PKD2 are widely expressed throughout different foetal
and adult tissues, explaining why ADPKD can affect extra-
renal tissues including the liver, the pancreas and the arter-
ies. In ADPKD kidneys, cysts originate from a small
number of nephrons and possess functional and molecular
characteristics of various nephron segments [3].
During normal human nephrogenesis, PKD1 mRNA is
absent from the uninduced mesenchyma and the emerging
ureteric bud. From 10 weeks, a strong PKD1 signal ap-
pears in the first set of differentiated proximal tubules
(PT) from their glomerular origin. From 10 to 24 weeks,
the differentiated PT express high levels of PKD1 mRNA.
At week 15, a discrete PKD1 expression is also detected in
the distal nephron and ureteric bud branches, persisting at
a moderate level during foetal life [4]. In mouse embryonic
kidneys, Pkd1 is not expressed in the ureteric bud and
comma and S-shaped bodies, and weakly expressed in in-
duced metanephric mesenchyme from embryonic Day 13.5
(E13.5), to increase intensely in differentiating PT from
E15.5 [5]. Several mouse models carrying mutations in
Pkd1 have been reported. All Pkd1 knockout (KO) embry-
os die in utero by developing massive polycystic kidney
disease, hydrops fetalis and polyhydramnios [5–10]. Some
models are also characterized by vascular fragility [7] and
cardiovascular and skeletal development defects [5], sug-
gesting that the type of mutation in Pkd1 may influence
the severity of the phenotype and the stage of lethality.
Taken together, these studies showed that polycystin-1
does not play a major role in early nephrogenesis, as the
latter is normal in Pkd1 mutant embryos [5–7]. Instead,
polycystin-1 may participate in epithelial cell differentia-
tion and tubular extension in late nephrogenesis.
While previous studies pointed to the severe renal cysto-
genesis and extrarenal phenotype of Pkd1 embryos, there
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has been no detailed investigation of the time-course and
segmental origin of the cysts. Early functional abnormali-
ties in human ADPKD include impaired urinary concen-
trating capacity [1,2] and urinary excretion of PT markers
[11]. However, the factors contributing to polyhydramnios
in Pkd1 KO mice, including potential abnormalities in the
placenta [12], remain unknown. In this study, we used a
mouse model with a targeted deletion of Pkd1, resulting
in a Pkd1-null allele [9], to investigate daily survival and
cystogenesis in utero, as well as placental morphology
and amniotic fluid (AF) volume and composition. Our data
show that the loss of Pkd1 is associated with a massive loss
of solutes from E13.5 along with increased cyclic adeno-
sine 3'5-monophosphate (cAMP) levels in the AF. These
functional abnormalities precede the renal cysts, which
are first detected in mesenchyme-derived glomerulus and
PT segments and later in the collecting ducts.
Materials and methods
Pkd1 mice and in utero analyses
Studies were conducted on a Pkd1 mouse model that was obtained by
targeting the exons 2 to 5 and part of the exon 6 of Pkd1, resulting in a
null allele [9,13]. The original stock of mice (mixed 129/sv/C57BL/6J
background) was later backcrossed (at least six generations) to the
C57BL/6J background. Heterozygous Pkd1 mice, aged 10–15 weeks,
were crossed to generate homozygous Pkd1−/− embryos. The gestational
age was dated by appearance of the vaginal plug on the morning after
mating, and designated as Day 0.5 (E0.5). Pregnant mice were sacrificed
by cervical dislocation, and a caesarean section was performed to remove
the uterus intact. The uterus was dissected and the embryos were removed
under sterile, RNase-free conditions. The survival rate was based on em-
bryos displaying a body movement or heart beating under microscopic
examination. The embryos were placed on ice-cold Petri dishes and dis-
sected to aspirate the AF and to harvest the kidneys. The studies covered
the embryonic days E12.5 to E18.5 among a total of 257 embryos. We
also used Pkd1del17–21βgeo mouse embryos to investigate the expression
of Pkd1 in early tubulogenesis [5]. All protocols complied with the Na-
tional Research Council Guide for the Care and Use of Laboratory Ani-
mals and were approved by the local ethics committee.
Antibodies and markers
Sheep polyclonal antibodies against megalin (a gift of Dr. P. Verroust,
INSERM, Paris, France) and uromodulin (Biodesign Int., Saco, ME);
goat polyclonal antibodies against PECAM-1 (CD31, Santa Cruz Bio-
technology, Santa Cruz, USA); rabbit polyclonal antibodies against aqua-
porin-1 (AQP1) (Chemicon-Millipore, Billerica, MA), aquaporin-2
(AQP2) (Sigma, Saint Louis, MO) and podocin (P35, a gift of Dr. C.
Antignac, INSERM); mouse monoclonal antibodies against polycystin-
1 (7E12, Santa Cruz Biotechnology); and Dolichos biflorus agglutinin
(DBA) lectin (Sigma) were used.
The rabbit polyclonal antibody, anti-leucine-rich repeats (LRR), was
raised against the N-terminal LRR domain of polycystin-1. Rabbits were
immunized with purified His-tagged LRR domain (amino acids 27–360)
expressed as a bacterial fusion protein; and antibodies purified using
protein-A agarose as previously described [14]. The specificity of the
purified anti-LRR antibodies was confirmed by ELISA (not shown)
and Western blot analysis against both the polycystin-1 N-terminal fusion
protein and the recombinant polycystin-1 LRR (Suppl. Fig. 1). Previous
studies have shown that the anti-LRR antibodies were able to immuno-
precipitate the in vitro translated N-terminal half of polycystin-1, and that
immunostaining was abolished with preadsorption of antibody with fu-
sion protein [14].
Immunohistochemistry
Embryonic kidney samples were fixed in 4% paraformaldehyde (Boehrin-
ger Ingelheim, Heidelberg, Germany) in 0.1 mol/L phosphate buffer, pH
7.4, prior to embedding in paraffin as described [13]. Six-micrometre sec-
tions were cut and stained with hematoxylin and eosin. Additional sec-
tions were incubated for 30 min with 0.3% hydrogen peroxide to block
endogenous peroxidase. Following incubation with 10% normal serum for
20 min, sections were incubated for 45 min with the primary antibodies
diluted in PBS containing 2% bovine serum albumin (BSA). After wash-
ing, sections were successively incubated with biotinylated secondary
anti-immunoglobulin (Ig) G antibodies, avidin–biotin peroxidase and
aminoethylcarbazole (Vectastain Elite, Vector Laboratories). The M.O.
M. kit (Vector Laboratories) was used for mouse-derived antibodies.
Sections were viewed under a Leica DMR coupled to a Leica DC300
digital camera (Leica, Heerbrugg, Switzerland). Kidney sections of both
Pkd1−/− and Pkd1+/+ embryos ranging from E13.5 to E18.5 (n = 4 per
embryonic day) were examined.
Staining for β-galactosidase activity in Pkd1del17–21βgeo kidneys
Staining for β-galactosidase activity in frozen tissue sections was carried
out as previously described [5]. Tissues were fixed in X-gal fixative (0.2%
paraformaldehyde (PFA), 0.1 M PIPES buffer, 2 mM MgCl2, 0.1 M
EGTA, pH 7.3) at 4ºC and cryoprotected in 30% sucrose/2 mM MgCl2
before being snap frozen on LN2 and stored at −160ºC in LN2 until sec-
tioned. Fifteen-micrometre tissue sections were fixed at 4°C for 10 min in
X-gal fixative and rinsed briefly in ice-cold PBS/2 mM MgCl2. The sec-
tions were permeabilized by washing in detergent rinse (0.1 M phosphate
buffer, pH 7.3, 2 mMMgCl2, 0.01% sodium deoxycholate, 0.02% NP-40)
at 4ºC for 30 min, and stained in X-Gal staining solution (1mg/ml X-gal,
0.1 M phosphate buffer pH 7.3, 2 mM MgCl2, 0.01% sodium deoxycho-
late, 0.02% NP-40, 5 mM potassium ferricyanide and 5 mM potassium
ferrocyanide) at 37°C overnight in the dark. Stained sections were washed
twice in PBS/2 mM MgCl2, rinsed in H2O and counterstained for 2 min
with nuclear fast red (Vector Laboratories). The sections were rinsed in
water for 10 min, dehydrated with 5-min exchanges through graded meth-
anol (50%, 70%, 90% and 100%) and cleared in Histoclear (Fischer Che-
micals). Sections were mounted using Vectamount (Vector Laboratories).
Morphometric analyses of the placenta
Volumic density of four different compartments of the placenta (the cho-
rionic plate with stem villi, the labyrinth, the spongiotrophoblast and the
giant cells) was determined by point counting, using a GF Planachromat
12.5× objective on a Jenamed 2 microscope (Jena, Jena, Germany)
equipped with GF-PW 10× oculars containing a 100 crosses grid. A ran-
dom whole histological cross-section was analysed for six placentas from
Pkd1+/+ and Pkd1−/− embryos at E13.5 by a pathologist unaware of the
mouse genotype.
Analyses of AF
The AF samples were prospectively collected from live embryos of preg-
nant Pkd1+/− females from E12.5 to E18.5. Each embryo was placed in-
side a pre-weighed chamber before inserting a BD Micro-Fine Insulin
needle, 29 G × 12.7 mm, into the amniotic sac for AF aspiration. After
careful aspiration, the foetal membrane was ruptured and opened up com-
pletely in order to collect all the remaining fluid. The total volume of the
AF was measured in pre-weighed sterile tubes (intra-assay error <5%).
Aliquots of AF were obtained at the time of aspiration and stored at
−20°C. The concentrations of sodium and glucose were measured with
Synchron CX5 PRO analyser (Beckman Coulter, Fullerton, CA). The
concentrations of the low-molecular-weight (LMW) protein CC16 (Clara
cell protein 16 kD) was determined using a sensitive radioimmunoassay
as described [15].
cAMP measurement
For cAMP measurement, AF (30 μl) was mixed with 300 μl of absolute
ethanol, vortexed and centrifuged at 3500 g for 20 min at 4°C. The su-
pernatant was collected and lyophilized using a Speed-Vac concentrator.
cAMP levels were determined using a cAMP [125I] Biotrak Assay (Amer-
sham, Buckinghamshire, UK) following the acetylation procedure de-
scribed in the assay. The lyophilized AF samples and cAMP standards
(ranging from 2 to 128 fmol/100 μl) were submitted to acetylation by
the addition of a mixture of acetic anhydride triethylamine (1:2; v:v).











A duplicate of 100 μl aliquots from all standards and samples was pi-
petted into polypropylene tubes, then 100 μl of antiserum (except in tubes
for the determination of non-specific), and 100 μl of cAMP [125I] were
added into all tubes, prior to being vortexed, and finally incubated for 4
h at 4°C. After the incubation, 500 μl of Amerelex-M secondary antibody
reagent was added to each tube. The tubes were vortexed and then incu-
bated for 10 min at room temperature. The antibody-bound fraction was
separated by centrifugation at 2500 g for 15 min, and the supernatant
liquid was discarded by careful aspiration. The radioactivity was counted
in duplicate for 2 min in a gamma counter.
Data analysis
Comparisons between groups were performed using two-tailed unpaired
Student's t-test (GraphPad, San Diego, CA). Significance level was
P < 0.05.
Results
Survival rate and polyhydramnios in Pkd1−/− embryos
Embryonic lethality was observed in Pkd1−/− embryos as
early as E13.5, with a survival rate that sharply declined
at E15.5. Only 25% (3/12) of Pkd1−/− embryos survived
at E18.5, and none at birth. By contrast, all wild-type and
heterozygous Pkd1 embryos survived to birth (Table 1).
The first abnormality found in Pkd1−/− embryos was
the polyhydramnios, consistently observed from E13.5
(Figure 1A–C). The time-course analysis revealed a pro-
gressive and continuous increase in the total AF volume
in Pkd1−/− mice, contrasting with the stability observed
between E12.5 and E17.5 in both wild-type and heterozy-
gous mice. The AF volume was significantly higher at all
time points from E13.5 to E18.5 in Pkd1−/− vs. both
Pkd1+/+ and Pkd1+/− embryos (Figure 1D).
Histological analysis of the Pkd1-mutant placentas
As abnormalities of the placental labyrinth layer have been
described in a Pkd1−/− mouse model (K. Piontek et al.,
unpublished work [12]), we performed a detailed mor-
phometry analysis of the placentas of Pkd1 mice at
E13.5, the first stage associated with polyhydramnios. This
analysis showed that the volumic density of each placental
compartment was similar between Pkd1+/+ and Pkd1+/−
Table 1. Survival rate of Pkd1-mutant embryos
Crossed mice Embryonic Pkd1−/− Pkd1+/+ Pkd1+/− Total embryos
n Age n: A (D) n: A (D) n: A (D) n
2 E12.5 3 (0) 3 (0) 12 (0) 18
5 E13.5 9 (1) 6 (0) 12 (0) 28
6 E14.5 12 (0) 9 (0) 17 (0) 38
7 E15.5 10 (4) 11 (0) 19 (0) 44
5 E16.5 5 (8) 10 (0) 16 (0) 39
5 E17.5 3 (8) 8 (0) 13 (0) 32
5 E18.5 3 (9) 9 (0) 15 (0) 36
4 At birth 0 (4) 6 (0) 13 (0) 23
A, alive; D, dead; n, number.






































Fig. 1. Polyhydramnios in Pkd1−/− embryos. (A–C) Pkd1−/− embryos with massive polyhydramnios shown here inside the mother's uterine membrane
at different stages of development in comparison with Pkd1+/+ wild-type embryos: (A) E13.5, (B) E15.5 (C) E16.5. Bar = millimetre scale. (D) Time-
course of amniotic fluid volume at each time point according to the Pkd1 genotype (n = 6 to 19 embryos at each time point). The total amniotic fluid
volume values were significantly higher in Pkd1−/− vs. Pkd1+/+ and Pkd1+/− from E13.5 to E18.5. *P < 0.0001; #P < 0.0001, Pkd1−/− vs. Pkd1+/−.











embryos, with no detectable abnormalities in the labyrinth
and the spongiotrophoblast (Suppl. Fig. 2).
Hydrops fetalis and vascular fragility in Pkd1−/− embryos
In addition to polyhydramnios, Pkd1−/− embryos showed a
typical phenotype of hydrops fetalis resulting in tissue
edema, detectable from E13.5 and throughout gestation
(Figure 2A–C). Edema of the back of the body caused a
vertical shape, preventing Pkd1−/− embryos from being
curved as the wild-type embryos. Moreover, the Pkd1−/−
embryos showed areas of focal haemorrhage in different
regions of the body, such as the neck and abdomen (Figure
2D, E). The vascular rupture could be observed as early as
E13.5 and continuing to E18.5.
Pattern of cystogenesis in the Pkd1−/− embryonic kidneys
Histological analysis (Figure 3) showed that the renal
cysts in Pkd1−/− embryos were first detected at E15.5
(Figure 3B), consistent with the other Pkd1-mutant mouse
models. The first cysts at E15.5 were located in the inter-
nal area of the kidney, and a large majority of them were
glomerular cysts characterized by the cystic enlargement
of the Bowman space and the presence of glomerular tufts
(Figure 3F and Figure 4). The glomerulocystic phenotype
was only observed for glomeruli located in the deep me-
dulla zone, whereas superficial glomeruli located in the
cortex among comma and S-shaped bodies were non-cystic
(Figure 4A). At high magnification, the cysts arise from the
dilation of the Bowman capsule, with flattened cells and
discontinuous cell lineage. The podocytes, typically orga-
nized in a crown surrounding the capillaries in the young
glomeruli, showed no abnormalities (Figure 4B). Immu-
nostaining for the endothelial marker CD31/PECAM-1
identified the normal glomerular vascularization in these
sections (Figure 4C, D).
From E16.5, cystogenesis progressed from the medulla
towards the cortical area, still involving glomeruli as well
as tubular segments (Figure 3G). By E18.5 the cysts
were detected in all areas of the kidney (Figure 3H).
Quantification revealed that glomerular cysts accounted
for ~65% (128/197) of the total number of cysts at
E15.5 and ~45% (110/246) at E16.5 (Table 2). Apart
from atrophic lesions of the glomerular tuft, which were
observed from E16.5, there was no evidence for fibrosis,
inflammatory infiltrate, tubular casts or epithelial hyper-
plasia in the Pkd1−/− kidneys. Of note, even in mutant
embryos, nephrogenesis continued on until birth in the
external cortex.
Segmental origin of the cysts in Pkd1-mutant kidneys
To further characterize the segmental origin of the cysts,
serial sections of Pkd1−/− kidneys were stained with mega-
lin, a multi-ligand receptor that is specifically expressed in
PT cells [16], and DBA lectin, a marker of the distal con-
voluted tubule and the collecting duct [17] (Figure 5). No










Fig. 2. Hydrops fetalis and vascular fragility in Pkd1−/− embryos. (A–C) Pkd1−/− embryos showed hydrops fetalis (generalized oedema, most visible
on the back of the body) at E13.5 (A), E15.5 (B) and E16.5 (C). D. Focal haemorrhage in a Pkd1−/− embryo aged E13.5, demonstrating vascular
fragility. E. High magnification of a Pkd1−/− embryo's back at E16.5, showing subcutaneous oedema and vascular fragility. Bar = millimetre scale.











profiles positive for megalin or DBA lectin were detected
(Figure 5A, E). At E15.5, some of the cysts at the cortico-
medullary junction were stained with megalin, whereas no
cysts were stained with DBA lectin (Figure 5B, F). At
E16.5, a fraction of cysts located in medulla and cortico-
medullary area were positive for megalin (70/246, 28%),
or less frequently, DBA lectin (42/246, 17%) (Figure 5C,
G; Table 2). There was no cross-reactivity between mega-
lin and DAB lectin in the same cyst (Figure 5B–H).
Further analyses showed that the staining for megalin,
which was strictly apical in wild-type and non-cystic










Fig. 3. Stages of renal development in Pkd1 embryos. Representative sections (hematoxylin and eosin staining) of Pkd1+/+ (A–D) and Pkd1−/− (E–H)
embryonic kidneys at different stages of development. Progressive cyst formation, starting from glomeruli and later extending to tubular segments, is
observed in Pkd1−/− kidneys beginning at E15.5 (F–H). Bar = 100 μm.











even absent in the epithelial cells lining PT cysts in the
Pkd1−/− kidneys (Figure 6). The glomerular cysts were
unstained, except for some megalin-positive PT cells iden-
tified at the urinary pole of the Bowman capsule. Only
~10% of the tubular cysts were negative for both markers
(Table 2). We could not obtain clear staining for AQP1
(PT marker), uromodulin (thick ascending limb marker)
or AQP2 or calbindin (collecting duct markers) at any
stage, even after antigen retrieval (data not shown). These
data show that, in this Pkd1-null mouse model, the first
renal cysts are detected at E15.5 in mesenchyme-origi-
nated tissues rather than ureteric bud-originated tissues,
and that a majority of glomerular cysts is observed at
E15.5 and E16.5.
Expression of Pkd1 and polycystin-1 during mouse
nephrogenesis
We next investigated the pattern of Pkd1 and polycystin-1
expression in the developing mouse (Figure 7). Using the
β-galactosidase reporter gene, Pkd1 expression was not
detected in the pronephros or mesonephros prior to the
development of the definitive metanephric kidney in the
Pkd1del17–21βgeo +/− mouse. From E13.5–E15.5, weak
Pkd1 expression was seen in the condensed mesenchyme
surrounding the ureteric bud tips and weakly in some
cells within the uncondensed mesenchyme but not in
the ureteric bud tips themselves. Pkd1 expression was al-








Fig. 4. Glomerular cysts in Pkd1-null embryos. (A, B) At E15.5, a typical picture of glomerulocystic kidney disease was observed in Pkd1−/− embryos.
The glomerulocystic phenotype was only observed for glomeruli located in the deep medulla zone, whereas superficial glomeruli located in the cortex
among comma and S-shaped bodies were non-cystic (A). At high magnification (B), the cysts arise from the dilation of the Bowman capsule, with
flattened cells and discontinuous cell lineage (asterisk). The podocytes, typically organized in a crown surrounding the capillaries in the young
glomeruli (arrows), showed no abnormalities. The start of early proximal tubules could be seen in some glomerular cysts, without tubular dilation at
E15.5. Immunostaining for CD31 (C–D) was used as a marker of glomerular vascularization in cysts identified at E18.5. Bar = 80 μm (A); 20 μm (B,
D); 40 μm (C).
Table 2. Segmental origin of the cysts in Pkd1-null embryonic kidneys
Age Kidney sections (n)a Glomerular cysts (n) Megalinb n DBA lectinb n Undefined cysts (n) Total cysts (n)
E13.5 8 0 ++ 0 + 0 0 0
E14.5 8 0 ++ 0 ++ 0 0 0
E15.5 10 128 ++ 54 ++ 0 15 197
E16.5 8 110 ++ 70 ++ 42 24 246
aThese sections were obtained from four to five embryos.
bStaining intensity: +, weak positive staining; ++, strong positive staining.











body to form the glomerulus. From E15.5, there was
marked upregulation of Pkd1 expression within the devel-
oping metanephros and in the glomerular parietal epithe-
lium, differentiating PT and collecting ducts (Figure 7A,
B). Vascular staining was also detected, whereas early














Fig. 5. Segmental origin of cysts in Pkd1−/− embryonic kidneys. Serial sections of Pkd1−/− embryonic kidneys at different stages of development
stained with megalin, a marker of the proximal tubule (A–D), and DBA lectin, a marker of the distal tubule and collecting duct (E–H). Non-cystic
tubule profiles are stained at E14.5, without cross-reactivity between the two markers (A, E). At E15.5, some cysts are stained with megalin (B),
whereas DBA staining is still restricted to non-cystic tubules (F). At E16.5 and E18.5, some cysts are stained with megalin, whereas other cysts
are positive for DBA lectin, indicating proximal vs. collecting duct origin respectively (C–D vs. G–H). There was no cross-reactivity between
megalin and DAB lectin in the same cyst. Bar = 100 μm.











cortex remained negative. Immunostaining for polycystin-
1 (anti-LRR antibodies) detected a specific signal in the
glomerular parietal epithelium and in the PT epithelial
cells in E15.5 Pkd1+/+ kidneys (Figure 7E–F), whereas
no specific staining was observed in the corresponding re-
gions of Pkd1−/− kidneys (Figure 7G). This staining pat-
tern was confirmed (although with a higher background)
when using the 7E12 antibody against polycystin-1 (data
not shown).
Massive loss of solutes and increased cAMP levels in AF
The AF collected from E13.5 to E16.5 was analyzed in
order to calculate the amount of solute excreted in each
genotype (Figure 8). The Pkd1−/− embryos were char-
acterized by a significantly higher excretion of sodium
and glucose from E13.5 through E16.5 (Figure 8A, B).
Time-course analysis of the LMW protein CC16 in the
AF of the wild-type embryos revealed a progressive de-
crease from E13.5 to E16.5, followed by an abrupt rise
at E17.5 as a marker of foetal lung growth, as previ-
ously described [15]. By contrast, the CC16 excretion
progressively increased from E13.5 to E16.5 in the
Pkd1−/− embryos, being significantly higher than the
wild-type at E15.5 and E16.5 (Figure 8C). Furthermore,
there was a progressive increase in the cAMP excreted
in the AF of Pkd1-null embryos at E14.5, and even
further at E15.5, which was concurrent with cystogen-
esis (Figure 8D). These data show that deletion of
Pkd1 is associated with a substantial loss of solutes,
including the LMW protein CC16 before the onset of
lung growth, and increased cAMP levels in the AF.
Discussion
In this study, we have analysed the consequences of










-/- +/+ + /+
Fig. 6. Distinct patterns of megalin immunoreactivity in Pkd1 kidneys. Immunolocalization of the multi-ligand receptor megalin in representative
sections of Pkd1−/− (A, B) and Pkd1+/+ (C, D) kidneys at E16.5 (A–C) and E18.5 (D). A distinct and well-delineated apical staining for megalin
is observed in non-cystic proximal tubule profiles of Pkd1−/− kidneys (A, arrows), similar to that observed in wild-type kidneys (C, D). This pattern
contrasts with the increased reactivity, loss of polarity and even loss of expression observed in the flattened cells lining adjacent cystic profiles (A,
asterisks; B, higher magnification). Bar = 40 μm (A, C, D); 20 μm (B).











stogenesis, the structure of the placenta and the AF
volume and composition in mouse embryos. The
Pkd1-null embryos start to die at E13.5, with consis-
tent features including hydrops fetalis, renal cysts and
vascular fragility, in absence of placental abnormali-
ties. This Pkd1-null model is characterized by an ear-
ly polyhydramnios, with an excessive loss of various
solutes, including cAMP, in the AF. These features
precede the development of renal cysts, which are
first detected in glomeruli and PT, and later in distal
nephron segments.
Nephrogenesis in mouse and man is characterized by a
repetitive and reciprocal induction between the ureteric
bud and the metanephric mesenchyme, resulting in the
formation of mature kidneys before birth. The first cysts
in Pkd1−/− embryonic kidneys are observed at E15.5,
starting in mesenchyme-originated tissues, with the ma-
jority of cysts arising from mature glomeruli and a signif-
icant proportion from the PT segments as indicated by
positive megalin staining. These events are reflected by
a rise in embryonic lethality at E15.5. The segmental cy-
stogenesis in our model is consistent with the pattern of
Pkd1 expression in the mouse as reported by Boulter et
al. [5] and further detailed here using lacZ staining on
developing kidneys from Pkd1del17–21βgeo +/− mice (Fig-
ure 7). In agreement with in situ hybridization data [18],
these studies show that Pkd1 expression is limited during









Fig. 7. Expression of Pkd1 and polycystin-1 in the developing mouse kidney. (A–D) LacZ staining for Pkd1 expression in Pkd1del17-21βgeo +/− mice.
The expression of Pkd1 in the glomerular parietal epithelium and in proximal and more distal tubule epithelial cells is seen at low magnification (panel
A, E16.5). Note that the renal capsule is also a site of Pkd1 expression. The glomerular and proximal tubular expression is detected as early as E15.5
(panel B). Panels C (+/−) and D (+/+) are positive and negative whole mount controls for the lacZ staining, respectively. (E–G) Immunostaining for
polycystin-1 (anti-LRR antibodies) in E15.5 Pkd1 kidneys. A clear signal is observed in the glomerular parietal epithelium and in the proximal tubule
epithelial cells of Pkd1+/+ kidneys (panels E and F). No specific staining is observed in the corresponding region of a Pkd1 KO kidney (panel G). Bar =
30 μm (A, F); 20 μm (B); 40 μm (E, G).











chyme and no expression in the ureteric bud. From
E15.5, Pkd1 expression increased dramatically in induced
mesenchymal cells, including maturing PT, and subse-
quently, more distal nephron segments [5]. The initial
and intense expression of Pkd1 in glomerular parietal
epithelium and PT is in line with the first cystic lesions
observed here and in the Pkd1del34/del34 mice [6]. Glomer-
ular cysts have also been reported in the Pkd1L/L mouse
model characterized by a severe phenotype including vas-
cular defect leading to haemorrhagic lesions and lethality
by E15.5 [7]. Furthermore, glomerular cysts were de-
tected in the adult kidneys from two models of transgenic
mice overexpressing normal PKD1 [19] or Pkd1 [20],
suggesting the importance of a precise regulation of poly-
cystin-1 expression for normal glomerular maturation and
tubulogenesis.
Hydrops fetalis, a term used to describe foetuses with
generalized oedema and cavity effusions, is observed in
the Pkd1−/− embryos like in the majority of Pkd1 KO
mice thus far [5,7–9]. Fluid balance in the foetus inte-
grates placental fluid transfer, capillary filtration, swal-
lowing, lung secretion and urine production [21].
Accordingly, many features observed in the Pkd1 mice
may explain an interstitial fluid accumulation, including
abnormal vascular permeability, cardiac malformations
and impaired renal function. The Pkd1−/− embryos investi-
gated here show a significant polyhydramnios, consistently
observed from E13.5 and throughout development. By con-
trast, the AF volume is stable across gestation in both wild-
type and heterozygous Pkd1 mice, followed by a sharp
decrease at E18.5, similar to the human and mouse situ-
ation [21,22]. In addition to our model, polyhydramnios
has only been reported in another Pkd1-null mouse [8].
Polyhydramnios may result from salt-losing tubulopathies
or increased foetal urine output secondary to diabetes in-
sipidus [23]. The AF fluid analyses demonstrated a mas-
sive loss of sodium and glucose in the Pkd1−/− embryos
starting at E13.5, i.e. 2 days before cystogenesis. There is
also an increased excretion of the LMW protein CC16 at
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Fig. 8. Time-course of solute excretion in the amniotic fluid of Pkd1 embryos. Total excretion of sodium (A), glucose (B), CC16 (C) and cAMP (D) in
the amniotic fluid of Pkd1+/+ vs. Pkd1−/− embryos. The excretion of sodium (A) and glucose (B) was higher in Pkd1−/− embryos during the course of
embryogenesis (*P < 0.0001, n = 4 to 15 at each embryonic day). The excretion of CC16 progressively decreased from E13.5 to E16.5 in the wild-type
embryos, followed by an abrupt rise at E17.5 due to foetal lung growth. By contrast, the CC16 excretion progressively increased from E13.5 to E16.5 in
Pkd1−/− embryos, being significantly higher than the wild-type at E15.5 and E16.5 (no viable embryo at E17.5) (C). The excretion of cAMP (D) was
significantly higher in Pkd1−/− vs. Pkd1+/+ embryos at E14.5 and further at E15.5 (*P < 0.02, #P < 0.0001, n = 4 at each embryonic day).











the sharp increase due to lung maturation [15]. CC16 is
typically reabsorbed by PT cells through the multi-ligand
megalin receptor pathway [16]. We showed previously
that the polarized expression of essential components
of the PT endocytic apparatus (e.g. ClC-5 and vacuolar
H+-ATPase subunits) is acquired at E15.5 [24]. The co-
expression of these molecules—including megalin as re-
ported here—immediately after the onset of glomerular
filtration [25] suggests an early maturation of PT function.
Together with the abnormal megalin expression observed
in PT-derived cysts, the increased excretion of CC16 in
the AF suggests that PT maturation may be altered in the
Pkd1−/− mice. In that respect, it is interesting to note that
an abnormal excretion of PT markers is an earliest func-
tional defect in patients with ADPKD [11].
Placental malformations may also cause abnormal
fluid balance in embryos. It has been suggested that
abnormalities of the placental labyrinth layer, detected
from E11.5, may cause Pkd1−/− foetal death [12]. By
contrast, our morphometry analysis did not detect ab-
normalities in the four placental compartments, includ-
ing the labyrinth layer (Suppl. Fig. 2). Thus, gross
placental abnormalities cannot explain the hydrops feta-
lis and polyhydramnios observed at E13.5 in our mod-
el. As the phenotype of Pkd1 mice is notoriously
dependent on the genetic background, one could spec-
ulate that differences in placenta morphology could re-
flect the different background (129Sv vs. C57BL/6J,
respectively) of the models.
We observed increased cAMP levels in the AF of
Pkd1−/− embryos at E14.5 and E15.5, concomitant to
cystogenesis. A progressive increase in cAMP in the
AF has been reported in normal human pregnancy
[26], which could reflect the progressive increase in glomer-
ular filtration and the maturation of PTand response to para-
thyroid hormone [27]. As glomerular f iltration—and
tubular maturation (see above)—start at E14.5 in mouse,
the increased levels observed at both E14.5 and E15.5 in
Pkd1-null embryos could reflect epithelial tubular produc-
tion, in addition to the maternal origin or production by the
amniotic membranes. Previous studies have shown that
increased levels of cAMP could play a major role in cyst
formation, through stimulation of fluid secretion and cell
proliferation (reviewed in [2]). In two cystic models
orthologous to human autosomal recessive PKD (PCK
rat) and nephronophthisis (pcy mouse), and one cystic
model orthologous to human ADPKD (Pkd2−/tm1Som
mouse), increased renal cAMP levels, paralleled with
higher expression of AQP2 and arginine vasopressin
(AVP) V2 receptor (V2R), have been reported [28–30].
Recently, Magenheimer et al. showed that embryonic
kidney tubules from E13.5 to E15.5 could be stimulated
by cAMP to form cyst-like structures of both proximal
tubule and collecting duct origin, a process that is signif-
icantly enhanced in Pkd1−/− embryonic kidneys [31].
The mechanism responsible for increased cAMP pro-
duction is probably multifactorial, involving the interac-
tion of circulating AVP with the V2R in the collecting
duct, together with decreased intracellular calcium le-
vels which can activate adenylyl cyclase 6 and/or inhi-
bits phosphodiesterase 1 [2]. The involvement of the
V2R pathway has been substantiated by the effects
of V2R antagonists in various genetic models of
PKD, with decreased renal cAMP levels associated
with slowed cyst and renal enlargement and improved
renal function, motivating a multicentric trial to test the
efficacy of a selective V2R antagonist in ADPKD pa-
tients [32].
The effects of V2R antagonists on cAMP generation
and the cystic phenotype in ADPKD are based on the as-
sumption that ADPKD cysts are predominantly of collect-
ing duct origin. However, the deletion of Pkd1 in this
mouse model is associated with predominant glomeru-
lar cysts at E15.5, followed by the development of
(megalin-positive) PT cysts and later by collecting duct
cysts. Accordingly, the V2R/AQP2 pathway, which is
restricted to the collecting duct and not expressed in
the glomerular parietal epithelium or in the PT, is
not necessary for cyst development at least in this
model. These findings in Pkd1 mice may also yield in-
sights into the segmental origin of cysts in human
ADPKD. In the developing human kidney, high
PKD1 expression first appears in differentiated PT
starting from their glomerular origin and later in the
distal nephron and the ureteric bud branches [4]. Glo-
merular cysts have been reported in patients with
ADPKD [33], including in a severe childhood case as-
sociated with a PKD1 deletion [34]. Earlier analyses of
cyst fluid composition, electric properties and immu-
noreactivity for segmental markers (including AQP1
and aminopeptidase) have identif ied a signif icant
number of cysts of PT origin co-existing with collect-
ing duct cysts in end-stage kidneys of ADPKD pa-
tients [3,35].
In conclusion, we show that the deletion of poly-
cystin-1 in this mouse model is reflected by polyhy-
dramnios and a massive loss of solutes, including
cAMP, in the AF. These changes precede the devel-
opment of renal cysts, first detected in glomeruli and
PT. These features give insights into the role of poly-
cystin-1 in renal development, the mechanisms of cy-
stogenesis and the tubular alterations encountered in
ADPKD.
Supplementary data
Supplementary data are available online at http://ndt.
oxfordjournals.org
Acknowledgements. The authors are grateful to Y. Cnops, H. Debaix, X.
Dumont, K. Parreira and L.Wenderickx for excellent assistance, and Profs.
A. Bernard, JP. Cosyns, A. Ong, Y. Pirson, A.Woolf and J. Zhou for helpful
discussions. These studies were supported by the Belgian agencies FNRS
and FRSM (3.4.592.06F), the ‘Fondation Alphonse & Jean Forton’, a Con-
certed Research Action (05/10-328), an Inter-university Attraction Pole
(IUAP P6/05), the Programme d’excellence Marshall DIANE (Région
Wallone), and the EUNEFRON (FP7, GA#201590) program of the Euro-
pean Community.
Conflict of interest statement. None declared.












1. Pirson Y, Chauveau D, Devuyst O. Autosomal dominant polycystic
kidney disease. Oxford Textbook of Clinical Nephrology. Oxford: Ox-
ford University Press, 2005; 3rd Edition, 2304–2324
2. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant
and recessive polycystic kidney diseases. Nature Clin Prac Neph
2006; 2: 40–55
3. Devuyst O, Beauwens R. Ion transport and cystogenesis: the para-
digm of autosomal dominant polycystic kidney disease. Advances
in Nephrology. St. Louis: Mosby, 1998; 28439–478
4. Chauvet V, Qian F, Boute N et al. Expression of PKD1 and PKD2
transcripts and proteins in human embryo and during normal kidney
development. Am J Pathol 2002; 160: 973–983
5. Boulter C, Mulroy S, Webb S et al. Cardiovascular, skeletal, and renal
defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl
Acad Sci USA 2001; 98: 12174–12179
6. Lu W, Peissel B, Babakhanlou H et al. Perinatal lethality with kidney
and pancreas defects in mice with a targetted Pkd1 mutation. Nat
Genet 1997; 17: 179–181
7. Kim K, Drummond I, Ibraghimov-Beskrovnaya O et al. Polycystin 1
is required for the structural integrity of blood vessels. Proc Natl
Acad Sci USA 2000; 97: 1731–1736
8. Lu W, Shen X, Pavlova A et al. Comparison of Pkd1-targeted mutants
reveals that loss of polycystin-1 causes cystogenesis and bone de-
fects. Hum Mol Genet 2001; 10: 2385–2396
9. Muto S, Aiba A, Saito Y et al. Pioglitazone improves the phenotype
and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet
2002; 11: 1731–1742
10. Nishio S, Hatano M, Nagata M et al. Pkd1 regulates immortalized
proliferation of renal tubular epithelial cells through p53 induction
and JNK activation. J Clin Invest 2005; 115: 910–918
11. Casal JA, Hermida J, Lens XM et al. A comparative study of three
kidney biomarker tests in autosomal dominant polycystic kidney dis-
ease. Kidney Int 2005; 68: 948–954
12. Allen E, Piontek KB, Garrett-Mayer E et al. Loss of polycystin-1 or
polycystin-2 results in dysregulated apolipoprotein expression in mu-
rine tissues via alterations in nuclear hormone receptors. Hum Mol
Genet 2006; 15: 11–21
13. Ahrabi AK, Terryn S, Valenti G et al. Pkd1 haploinsufficiency causes
a syndrome of inappropriate antidiuresis in mouse. J Am Soc Nephrol
2007; 18: 1740–1753
14. Ibraghimov-Beskrovnaya O, Dackowski WR, Let F et al. Polycystin:
in vitro synthesis, in vivo tissue expression, and subcellular localiza-
tion identifies a large membrane-associated protein. Proc Natl Acad
Sci USA 1997; 94: 6397–6402
15. Halatek T, Hermans C, Broeckaert F et al. Quantification of Clara
cell protein in rat and mouse biological fluids using a sensitive im-
munoassay. Eur Respir J 1998; 11: 726–733
16. Christensen EI, Brin H. Megalin and cubilin: multifunctional endo-
cytic receptors. Nat Rev Mol Cell Biol 2002; 3: 256–266
17. Murata F, Tsuyama S, Suzuki S et al. Distribution of glycoconjugates
in the kidney studied by use of labelled lectins. J Histochem Cyto-
chem 1983; 31: 139–144
18. Guillaume R, D'Agati V, Daoust M et al. Murine Pkd1 is a develop-
mentally regulated gene from morula to adulthood: role in tissue con-
densation and patterning. Dev Dyn 1999; 214: 337–348
19. Pritchard L, Sloane-Stanley JA, Sharpe JA et al. A human
PKD1 transgene generates functional polycystin-1 in mice and
is associated with a cystic phenotype. Hum Mol Genet 2000;
9: 2617–2627
20. Thivierge C, Kurbegovic A, Couillard M et al. Overexpression of
PKD1 causes polycystic kidney disease. Mol Cell Biol 2006; 26:
1538–1548
21. Brace RA, Wolf EJ. Normal amniotic fluid volume changes
throughout pregnancy. Am J Obstet Gynecol 1989; 161:
382–389
22. Cheung CY, Brace RA. Amniotic fluid volume and composi-
tion in mouse pregnancy. J Soc Gynecol Investig 2005; 12:
558–562
23. Kirshon B. Fetal urine in hydramnios. Obstet Gynecol 1989; 73:
240–242
24. Jouret F, Igarashi T, Gofflot F et al. Comparative ontogeny, proces-
sing, and segmental distribution of the renal chloride channel, ClC-5.
Kidney Int 2004; 65: 198–208
25. Loughna S, Landels E, Woolf AS. Growth factor control of
developing kidney endothelial cells. Exp Nephrol 1996; 4:
112–118
26. Yuen BH, Wittmann B, Staley K. Cyclic adenosine 3', 5'-mono-
phosphate (cAMP) in pregnancy body fluids during normal and
abnormal pregnancy. Am J Obstet Gynecol 1976; 125: 597–602
27. Webster SK, Haramati A. Developmental changes in the phosphaturic
response to parathyroid hormone in the rat. Am J Physiol 1985; 249:
F251–F255
28. Gattone VH, Xiaofang W, Harris PC et al. Inhibition of renal cystic
disease development and progression by a vasopressin V2 receptor
antagonist. Nature Medicine 2003; 9: 1323–1326
29. Torres VE, Xiaofang W, Qian Q et al. Effective treatment of an ortho-
logous model of autosomal dominant polycystic kidney disease. Na-
ture Medicine 2004; 10: 363–364
30. Wang X, Gattone V 2nd, Harris PC et al. Effectiveness of vasopressin
V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic
kidney disease development in the PCK rat. J Am Soc Nephrol
2005; 16: 846–851
31. Magenheimer BS, St John PL, Isom KS et al. Early embry-
onic renal tubules of wild-type and polycystic kidney disease
kidneys respond to cAMP stimulation with cystic fibrosis
transmembrane conductance regulator/Na+, K+, 2Cl− co-trans-
porter-dependent cystic dilation. J Am Soc Nephrol 2006; 17:
3424–3437
32. Torres VE, Bankir L, Grantham JJ. A case for water in the treat-
ment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4:
1140–1150
33. Verani RR, Silva FG. Histogenesis of the renal cysts in adult (auto-
somal dominant) polycystic kidney disease: a histochemical study.
Mod Pathol 1988; 1: 457–463
34. Torra R, Badenas C, Darnell A et al. Autosomal dominant poly-
cystic kidney disease with anticipation and Caroli's disease asso-
ciated with a PKD1 mutation. Kidney Int 1997; 52: 33–38
35. Devuyst O, Burrow CR, Smith BL et al. Expression of aquaporins-1
and -2 during nephrogenesis and in autosomal dominant polycystic
kidney disease. Am J Physiol 1996; 271: F169–F183
Received for publication: 16.3.09; Accepted in revised form: 22.10.09
1078 A.K. Ahrabi et al.
 at Y
ale U
niversity on D
ecem
ber 20, 2011
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
